Table 1.
Patients’ Demographics
| Characteristic Data | All Patients * (n=261) | First-Treated Patients* (n=111) | Re-Treatment Patients* (n=150) | P value |
|---|---|---|---|---|
| Mean age, mean ± SD, years | 52.3 ± 15.4 | 53.9 ± 16.9 | 51.1 ± 14.2 | 0.159 |
| Gender, no. (%) | <0.001 | |||
| Male | 116 (44.4) | 64 (57.7) | 52 (34.7) | |
| Female | 145 (55.6) | 47 (42.3) | 98 (65.3) | |
| Endoscopic findings, no. (%) | ||||
| Chronic superficial gastritis | 146 (55.9) | 56 (50.5) | 90 (60.0) | 0.124 |
| Chronic atrophic gastritis | 115 (44.1) | 55 (49.5) | 60 (40.0) | — |
| Duodenal ulcer | 34 (13.0) | 16 (14.4) | 18 (12.0) | 0.567 |
| Gastric ulcer | 8 (3.1) | 4 (3.6) | 4 (2.7) | 0.943 |
| Diagnosis of Infection before treatment, no. (%) | ||||
| Pathology | 261 (100) | 111 (100) | 150 (100) | — |
| Diagnosis of Infection after treatment, no. (%) | ||||
| UBT (13C-urea breath test) | 239 (91.6) | 104 (93.7) | 135 (90.0) | 0.288 |
| Pathology | 30 (11.5) | 7 (6.3) | 23 (15.3) | 0.024 |
| CYP2C19 genotypesa, no. (%) | 0.150 | |||
| Rapid metabolizer (RM) | 108 (45.6) | 51 (53.1) | 57 (40.4) | |
| Intermediate metabolizer (IM) | 105 (44.3) | 36 (37.5) | 69 (48.9) | |
| Poor metabolizer (PM) | 24 (10.1) | 9 (9.4) | 15 (10.6) | |
| Lost to follow up, no. (%) | 6 (2.3) | 3 (2.7) | 3 (2.0) | 1.000 |
Notes: *A total of 261 patients were retrospectively analyzed, including 111 patients who were treated for the first time (one group as First-treated) and 150 patients who failed at least once in bismuth quadruple therapy (another group as Re-treatment). aData were available in 237 patients, including 96 in first-treated and 141 in re-treated patients.